Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA.
J Nucl Med. 2010 Feb;51(2):311-28. doi: 10.2967/jnumed.108.058651. Epub 2010 Jan 15.
The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.
自 20 世纪初以来，人们就已经认识到α粒子发射体治疗癌症的潜力。放射性核素靶向递送和放射性核素缀合化学的进步，以及更适合临床使用的α发射体的可用性增加，最近导致了用α粒子发射体标记的放射性药物的患者试验。尽管α发射体已经研究了几十年，但它们目前在人类中的靶向治疗应用是一个重要的里程碑。这项工作的目的是回顾与靶向α粒子发射体治疗相关的领域，并为人类α粒子发射体剂量学提供指导和建议。
